Ahmed O Kaseb

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 117:2478-88. 2011
  2. doi request reprint Multidisciplinary management of hepatocellular carcinoma
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Recent Results Cancer Res 190:247-59. 2013
  3. doi request reprint Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncology 82:67-74. 2012
  4. pmc I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Oncology 80:373-81. 2011
  5. pmc Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:3892-9. 2011
  6. pmc Reassessing hepatocellular carcinoma staging in a changing patient population
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex, USA
    Oncology 86:63-71. 2014
  7. pmc Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex, USA
    Oncology 85:197-203. 2013
  8. pmc Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
    Ishwaria M Subbiah
    Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 6:28453-62. 2015
  9. pmc Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 119:3334-42. 2013
  10. doi request reprint Radiation treatment outcomes for unresectable hepatocellular carcinoma
    Heath D Skinner
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Acta Oncol 50:1191-8. 2011

Collaborators

Detail Information

Publications18

  1. pmc V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 117:2478-88. 2011
    ....
  2. doi request reprint Multidisciplinary management of hepatocellular carcinoma
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Recent Results Cancer Res 190:247-59. 2013
    ..This chapter aims to place current treatment strategies within the framework of a multidisciplinary approach with special emphasis on pretreatment evaluation, staging, and the selection of an appropriate treatment strategy...
  3. doi request reprint Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncology 82:67-74. 2012
    ..A phase II study was performed to evaluate the efficacy and tolerability of bevacizumab and erlotinib in advanced hepatocellular carcinoma (HCC) patients, and to investigate clinical and molecular predictors of outcome...
  4. pmc I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Oncology 80:373-81. 2011
    ....
  5. pmc Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:3892-9. 2011
    ..The study objective was to improve prognostic stratification of patients with HCC...
  6. pmc Reassessing hepatocellular carcinoma staging in a changing patient population
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex, USA
    Oncology 86:63-71. 2014
    ....
  7. pmc Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex, USA
    Oncology 85:197-203. 2013
    ..Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare variant of HCC. We report an analysis of the clinicopathologic features, treatment outcomes, and prognostic indicators of 94 cases...
  8. pmc Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
    Ishwaria M Subbiah
    Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 6:28453-62. 2015
    ..Given the rapid advanced in drug development and emergence of novel agents, we analyzed the characteristics and outcomes of HCC patients treated on early phase trials with an emphasis on targeted therapies...
  9. pmc Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 119:3334-42. 2013
    ....
  10. doi request reprint Radiation treatment outcomes for unresectable hepatocellular carcinoma
    Heath D Skinner
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Acta Oncol 50:1191-8. 2011
    ..Data regarding the use of radiotherapy is limited in patients from populations without endemic viral hepatitis. We examine the outcomes for patients treated with radiotherapy in the modern era at a single institution...
  11. ncbi request reprint Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
    Ishwaria M Subbiah
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:153-62. 2013
    ..Patients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease...
  12. doi request reprint Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:4895-906. 2009
    ..Cancer 2009. (c) 2009 American Cancer Society...
  13. pmc Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma
    Reham Abdel-Wahab
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 6:21193-207. 2015
    ..S. independent cohorts. Our current study aimed to validate the IGF-CTP score in patients who have different demographics and risk factors...
  14. pmc Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis
    Randa Tao
    Randa Tao, Sunil Krishnan, Priya R Bhosale, Milind M Javle, Thomas A Aloia, Rachna T Shroff, Ahmed O Kaseb, Andrew J Bishop, Cameron W Swanick, Eugene J Koay, Howard D Thames, Prajnan Das, and Christopher H Crane, The University of Texas MD Anderson Cancer Center, Houston, TX and Theodore S Hong, Harvard Medical School, Boston, MA
    J Clin Oncol 34:219-26. 2016
    ..Advances in radiotherapy (RT) techniques and image guidance have enabled ablative doses to be delivered to large liver tumors. This study evaluated the effects of RT dose escalation in the treatment of IHCC...
  15. pmc HER2/neu-directed therapy for biliary tract cancer
    Milind Javle
    Department of Gastrointestinal GI Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit Number 426, Room Number FC10 3062, Houston, TX, 77030, USA
    J Hematol Oncol 8:58. 2015
    ..HER2/neu amplification is associated with response to HER2/neu-directed therapy in breast and gastric cancers. However, the efficacy of HER2/neu-targeted therapy in biliary cancers is unknown...
  16. doi request reprint Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival
    Martin Palavecino
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Surgery 145:399-405. 2009
    ..Perioperative outcome and survival after major hepatic resection for HCC, with and without PVE, were investigated...
  17. doi request reprint TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications
    Silvana C Faria
    Department of Diagnostic Radiology, Unit 1473, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Abdom Imaging 39:1070-87. 2014
    ....